Our Science
Direct Biologics has developed the next generation of naturally bioactive products for regenerative therapies. Our novel technologies are used for developing Extracellular Vesicle (EV) products derived from adult human mesenchymal stem/stromal cells, which contain bioactive molecules with clinical therapeutic potential.
Our Mission
Direct Biologics is dedicated to delivering the next generation of medical therapeutics that will revolutionize the treatment of human disease.
Direct Biologics is at the forefront of innovation as a premier science-driven cGMP manufacturer of regenerative biologic products. Our company prioritizes delivering cutting-edge clinical and scientific insights through extensive research efforts. Leveraging profound expertise in cellular and regenerative therapies, Direct Biologics has pioneered groundbreaking advancements in therapeutic biologics with the introduction of EVs of unparalleled quality and safety.
News
Stay up to date and browse our latest press releases.
Direct Biologics Announces Publication of Significant Survival Benefit with ExoFlo™ in its Phase 2 Randomized Controlled Clinical Trial in the Journal CHEST
July 12, 2023
Read More →Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease
April 26, 2023
Read More →Direct Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects
April 26, 2023 • Read More →
Virginia mother reunited with newborn after going into COVID-induced coma
July 17, 2024 • Read More →
Contact Us
Send a Message
Contact Info
Email Address
info@directbiologics.com
Phone Number
(800) 791-1021
Mailing Address
Direct Biologics 5301 Southwest Parkway Building 1, Suite 415 Austin, Texas 78735, US